Specialty Pharmaceuticals

Articles for Specialty Pharmaceuticals

The smallest overall increase in the MMI in 15 years is masked by the fact that employees are bearing an increasingly large share of healthcare costs.
At the recently held NCCN healthcare policy summit in Washington, DC, experts delved into various models being evaluated to reduce healthcare utilization in oncology care.
As part of the one-on-one The Clinical and Reimbursement Landscape of Immuno-Oncology interview series on PD-1 inhibitors, Michael Kolodziej, MD, and Bruce Feinberg, DO, considered the implications for coverage and treatment pathways when 2 different molecules have the same target and indications. This discussion also addressed efficacy, toxicity, and cost of multiple agents.
Coverage from the 64th Scientific Sessions of the American College of Cardiology.
Description of strategies that employers can consider to better manage their PBM relationship to optimize their pharmacy benefit costs.
Specialty drugs expected to account for 40% of total prescription spending by 2016, according to Catamaran Corporation.
Specialty pharmaceuticals are changing the lives of patients with cancer and chronic conditions, but their high cost and increased used has drawn the scrutiny of payers. A review in this month's issue of The American Journal of Managed Care, which examined studies involving therapies for rheumatoid arthritis, multiple sclerosis, and breast cancer, found that when these drugs are used with the right patients, the value for patients is high.
This study examines whether patients treated with specialty pharmaceuticals have improved outcomes compared with patients treated with conventional therapies, and evaluates costs associated with these treatments.
Clinical Pathways Compendium
COPD Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium